公司概覽
業務類別 Biotechnology
業務概覽 Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
公司地址 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
電話號碼 +1 914 847-7000
傳真號碼 --
公司網頁 https://www.regeneron.com
員工數量 15410
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Leonard S. Schleifer,M.D.,PhD Co-Chairman of the Board, Co-President and Chief Executive Officer 美元 1.98M 24/04/2026
Dr. George D. Yancopoulos,M.D.,PhD Co-Chairman of the Board, Co-President and Chief Scientific Officer 美元 1.98M 24/04/2026
Mr. Joseph J. Larosa Executive Vice President, General Counsel and Secretary 美元 916.06K 24/04/2026
Mr. Daniel P. Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply 美元 983.38K 24/04/2026
Ms. Marion McCourt Executive Vice President, Commercial -- 24/04/2026
Mr. Christopher R. Fenimore Executive Vice President, Finance and Chief Financial Officer 美元 725.00K 24/04/2026
Mr. Andrew J Murphy Executive Vice President and Co-Chief Scientific Officer 美元 819.67K 24/04/2026
Mr. Jason Pitofsky Senior Vice President and Controller -- 24/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Arthur Frederick Ryan Independent Director 24/04/2026
Dr. Leonard S. Schleifer,M.D.,PhD Co-Chairman of the Board, Co-President and Chief Executive Officer 24/04/2026
Dr. Joseph L. Goldstein,M.D. Independent Director 24/04/2026
Dr. N. Anthony Coles, M.D. Independent Director 24/04/2026
Dr. Michael S. Brown, M.D. Independent Director 24/04/2026
Dr. Craig B. Thompson,M.D. Independent Director 24/04/2026
Ms. Christine A. Poon Lead Independent Director 24/04/2026
Dr. George D. Yancopoulos,M.D.,PhD Co-Chairman of the Board, Co-President and Chief Scientific Officer 24/04/2026
Mr. George L. Sing Independent Director 24/04/2026
Dr. David P. Schenkein, M.D. Independent Director 24/04/2026
Dr. Bonnie L. Bassler, PhD Independent Director 24/04/2026
Dr. Huda Y. Zoghbi, M.D. Independent Director 24/04/2026
Ms. Kathryn Guarini, PhD Independent Director 24/04/2026
 
所屬ETF (更新日期: 01/08/2026 04:18)
代號 名稱 佔比% 持有日期
VOTETCW Transform 500 ETF0.002%29/07/2026
JHMLJHancock Multifactor Large Cap ETF0.002%29/07/2026
CVLCCalvert US Large-Cp Cor Rspnb ETF0.002%28/07/2026
PFDEPathfinder Disciplined US Equity ETF0.002%29/07/2026
ISPYProShares S&P 500 High Income ETF0.002%29/07/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.002%29/07/2026
SFTYHorizon Managed Risk ETF0.002%29/07/2026
LSTLeuthold Select Industries ETF0.002%29/07/2026
IQQQProShares Nasdaq-100 High Income ETF0.002%29/07/2026
DFALDimensional US Large Cp Cor Eq Mkt ETF0.001%29/07/2026
GRXGabelli Health & Wellness0.001%31/03/2026
HRTSTema Heart & Health ETF0.001%29/07/2026
FLCCFederated Hermes MDT Large Cap Core ETF0.001%29/07/2026
BAMVBrookstone Value Stock ETF0.001%24/07/2026
JPUSJPMorgan Diversified Return US Eq ETF0.001%29/07/2026
IQQiShares Nasdaq 100 ETF0.001%28/07/2026
MFUSPIMCO RAFI Dyn Multi-Factor US Eq ETF0.001%27/07/2026
EQALInvesco Russell 1000 Equal Weight ETF0.001%29/07/2026
SIZEiShares MSCI USA Size Factor ETF0.001%28/07/2026
DIVEDana Concentrated Dividend ETF0.001%29/07/2026
  1    2    3    4    5    6    7    8    9    10   11    12    13    14    15    16    17    18    19    20    21    22    23    24  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.